Resources & Guides

Mounjaro (tirzepatide) treats type 2 diabetes by activating two incretin receptors at once. Here is the organ-level physiology, the SURPASS-1 evidence behind its 2022 FDA approval, and how it compares to Ozempic in head-to-head trials.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

A tirzepatide constipation guide covering the mechanism, brand-correct FDA label rates for Mounjaro and Zepbound, relief strategies, and when constipation becomes an emergency.

Tirzepatide has two FDA-approved brand names, both from Eli Lilly: Mounjaro for type 2 diabetes (May 2022, NDA 215866) and Zepbound for chronic weight management (November 2023, NDA 217806). Same molecule, two indications, two boxes.

Mounjaro (tirzepatide) is Eli Lilly's once-weekly injectable for type 2 diabetes, FDA-approved May 2022. The first dual GIP/GLP-1 receptor agonist, with a 2.5 to 15 mg dose ladder and SURPASS trial backing.

Zepbound and Ozempic are approved for different conditions. Zepbound targets weight management; Ozempic targets type 2 diabetes. Compare tirzepatide vs semaglutide across mechanisms, trial results, dosing, and cost.

Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) on both HbA1c reduction and weight loss in the SURPASS-2 trial. Ozempic holds the cardiovascular edge. Full comparison inside.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.